Loading stock data…
SAB Biotherapeutics (SABS)
$3.72
Pre-Market$3.94+0.22 (+5.91%)· Last close Sep 4
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
SAB Biotherapeutics, Inc. in the Healthcare sector is trading at $3.63 with a market capitalization of $295M. Wall Street consensus targets $11.64 (11 analysts), implying a +220.6% move over the next 12 months. The stock is currently 30% below its 52-week high of $5.15, remaining 5.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +220.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$23.38M↓ | -$20.00M↓ | -$15.77M↓ | -$12.68M↓ | -$9.73M |
| Net Income | -$22.49M↓ | -$18.87M↓ | -$16.86M↓ | $45.45M↑ | -$10.11M |
Peer Comparison
JNJUNHPFE
Fundamentals
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$294.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-0.18%
Volume
Today's trading volume
110,633
Recent News
SAB Biotherapeutics Q2 Earnings Call Highlights
SAB Biotherapeutics (NASDAQ:SABS) said its registrational Phase IIb SAFEGUARD trial of SAB-142 in newly diagnosed Stage 3 Type 1 diabetes remains on track to complete enrollment in the fourth quarter of 2026, with top-line data expected in the second half of 2027. Chief Executive Officer Samuel Rei
SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ...
Company on track to complete SAFEGUARD enrollment in Q4 2026 while expanding its pipeline with the PRIZE-HAPG study.
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment
SAB Biotherapeutics Inc. (NASDAQ:SABS) is one of the 10 best stocks under $10 that could triple. On July 7, SAB Biotherapeutics Inc. (NASDAQ:SABS) and Breakthrough T1D, a leading research and advocacy firm for type 1 diabetes, disclosed that Breakthrough T1D has awarded a research grant to Michael J. Haller, M.D., Chief Pediatric Endocrinologist and Professor […]
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?
SAB Biotherapeutics, Inc. (NASDAQ:SABS) ranks among the overlooked penny stocks to buy right now, supported by strong upside potential. Back-to-back bullish analyst calls are pointing to a wide gap between the company’s market value and the opportunity Wall Street sees in its lead diabetes program. On June 24, 2026, Barclays analyst Eliana Merle initiated coverage […]
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)
SAB Biotherapeutics Inc. (NASDAQ:SABS) is one of the 10 best stocks under $10 offering more than 50% upside. On June 24, Eliana Merle from Barclays initiated coverage of SAB Biotherapeutics Inc. (NASDAQ:SABS) with a target price of $13, and assigned an Overweight rating to the stock. As per Merle’s projections, the stock currently offers a […]